Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.

MLA

Slatopolsky, E., et al. “Marked Suppression of Secondary Hyperparathyroidism by Intravenous Administration of 1,25-Dihydroxy-Cholecalciferol in Uremic Patients.” The Journal of Clinical Investigation, vol. 74, no. 6, Dec. 1984, pp. 2136–43. EBSCOhost, https://doi.org/10.1172/JCI111639.

APA

Slatopolsky, E., Weerts, C., Thielan, J., Horst, R., Harter, H., & Martin, K. J. (1984). Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. The Journal of Clinical Investigation, 74(6), 2136–2143. https://doi.org/10.1172/JCI111639

Chicago

Slatopolsky, E, C Weerts, J Thielan, R Horst, H Harter, and K J Martin. 1984. “Marked Suppression of Secondary Hyperparathyroidism by Intravenous Administration of 1,25-Dihydroxy-Cholecalciferol in Uremic Patients.” The Journal of Clinical Investigation 74 (6): 2136–43. doi:10.1172/JCI111639.